Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.

T Asselah, Christophe HEZODE, RB Qaqish, M ElKhashab, T Hassanein, G Papatheodoridis, JJ Feld, C Moreno, S Zeuzem, P Ferenci, Y Yu, R Redman, T Pilot-Matias, N Mobashery,

Lencet Gastroenterol Hepatol. 01/09/2016;1(1) : 25-35 10.1016/S2468-1253(16)30001-2. 16/06/2016

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.

GR Foster, K Chayama, WL Chuang, H Fainboim, M Farkkila, A Gadano, GB Gaeta, Christophe HEZODE, Y Inada, J Heo, H Kumada, SN Lu, P Marcellin, C Moreno, SK Roberts, SI Strasser, AJ Thompson, J Toyota, SW Paik, JM Vierling, AL Zignego, D Cohen, F McPhee, M Wind-Rotolo, S Srinivasan, M Hruska, H Myler, SD Portsmouth,

Springerplus. 19/08/2016;5(1) : 1365 10.1186/s40064-016-2920-z.

Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension.

L Savale, MC Chaumais, D Montani, X Jais, Christophe HEZODE, TM Antonini, A Coilly, JC Duclos-Vallee, D Samuel, G Simonneau, M Humbert, O Sitbon,

Chest. 01/07/2016;150(1) : 256-258 10.1016/j.chest.2016.04.031.

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.

ZM Younossi, M Stepanova, J Feld, S Zeuzem, I Jacobson, K Agarwal, Christophe HEZODE, F Nader, L Henry, S Hunt,

J Hepatol. 01/07/2016;65(1) : 33-39 10.1016/j.jhep.2016.02.042 05/03/2016

Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.

Christophe HEZODE, Stephane CHEVALIEZ, G Scoazec, Alexandre SOULIER, A Varaut, Magali BOUVIER-ALIAS, Isaac RUIZ, F Roudot-Thoraval, A Mallat, Cyrille FERAY, Jean-Michel PAWLOTSKY,

Hepatology 01/06/2016;63(6) : 1809-1816 10.1002/hep.28491 10/03/2016

Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care.

Stephane CHEVALIEZ, Lila POITEAU, I Rosa, Alexandre SOULIER, F Roudot-Thoraval, S Laperche, Christophe HEZODE, Jean-Michel PAWLOTSKY,

Clin Microbiol Infect. 01/05/2016;22(5) : 459.e1-6 10.1016/j.cmi.2016.01.009. 22/01/2016

Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots.

Lila POITEAU, Alexandre SOULIER, I Rosa, F Roudot-Thoraval, Christophe HEZODE, Jean-Michel PAWLOTSKY, Stephane CHEVALIEZ,

J Viral Hepat. 01/05/2016;23(5) : 399-401 10.1111/jvh.12501 01/02/2016

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).

V Leroy, P Angus, JP Bronowicki, GJ Dore, Christophe HEZODE, S Pianko, S Pol, K Stuart, E Tse, F McPhee, R Bhore, MJ Jimenez-Exposito, AJ Thompson,

Hepatology. 01/05/2016;63(5) : 1430-1441 10.1002/hep.28473. 04/05/2016

Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring.

Alexandre SOULIER, Lila POITEAU, I Rosa, Christophe HEZODE, F Roudot-Thoraval, Jean-Michel PAWLOTSKY, Stephane CHEVALIEZ,

J Infect Dis. 01/04/2016;213(7) : 1087-1095 10.1093/infdis/jiv423. 02/09/2015

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.

S Zeuzem, Christophe HEZODE, JP Bronowicki, V Loustaud-Ratti, F Gea, M Buti, A Olveira, T Banyai, MT Al-Assi, J Petersen, D Thabut, A Gadano, R Pruitt, M Makara, M Bourliere, S Pol, M Beumont-Mauviel, S Ouwerkerk-Mahadevan, G Picchio, M Bifano, F McPhee, N Boparai, K Cheung, EA Hughes, S Noviello,

J Hepatol. 01/02/2016;64(2) : 292-300 10.1016/j.jhep.2015.09.024. 08/10/2015